Semaglutide is a long-acting GLP-1 receptor agonist (GLP-1RA). GLP-1RA activates the GLP-1 receptor by simulating natural GLP-1, enhancing insulin secretion in a glucose concentration dependent manner, inhibiting glucagon secretion, and delaying gastric emptying. It reduces food intake through central appetite inhibition, thereby achieving the effects of reducing blood sugar and weight loss.

    GLP-1RA has become one of the best-selling hypoglycemic drugs in the world. It not only has significant hypoglycemic effects and low risk of hypoglycemia when used alone, but also has effects such as weight loss, blood pressure reduction, and improving blood lipid profile. It is precisely because of its therapeutic effect in weight loss that it has attracted the attention of the weight loss population.